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Abstract
Background: Idiopathic membranous nephropathy (IMN) is a major cause of nephrotic syndrome among adults.
Considering the natural course of IMN, when to treat and with which immunosuppressive treatment need to be
carefully considered in such patients. A combination of tripterygium wilfordii multiglycosides (TWG) and prednisone
may be an effective option for treating patients with IMN.
Methods: In this prospective cohort study, we enrolled patients with biopsy-proven IMN at our kidney centre. One
cohort received TWG combined with prednisone, whereas another cohort received tacrolimus (TAC) combined with
prednisone, for 36 weeks. The primary outcome was the remission rate, whereas the secondary outcomes included
the time to remission, relapse rate, changes in serum albumin levels and daily urinary protein levels, estimated
glomerular filtration rate, and adverse events.
Results: A total of 53 patients with IMN met the criteria for enrolment, and all patients completed the therapy. At
the end of the 36-week therapy, remission (either partial remission [PR] or complete remission [CR]) was observed
in 20 patients (86.9 %) receiving TWG and in 27 patients (90.0 %) receiving TAC (p > 0.05), whereas CR was noted in
12 patients (52.2 %) receiving TWG and 14 patients (46.7 %) receiving TAC (p > 0.05). The probability of remission
was similar for both the TWG and TAC groups (p > 0.05, by log-bank test). The mean time for achieving remission
was 11.8 ± 12.5 weeks in the TWG group and 8.5 ± 9.1 weeks in the TAC group (p > 0.05).
Conclusions: The combination of TWG and predisone is an effective and safe therapy for IMN.
Keywords: Idiopathic membranous nephropathy, Tripterygium wilfordii Hook F, Tripterygium wilfordii
multiglycosides, Tacrolimus
Background
Idiopathic membranous nephropathy (IMN) is one of
the most common causes of nephrotic syndrome in
adults. If no treatment is administered, IMN may lead to
various outcomes. Although 30 % of patients with IMN
experience spontaneously complete (CR) or partial re-
mission (PR) [1], 30–40 % of patients develop end-stage
renal disease (ESRD) within 5–15 years [2]. Considering
the variable natural course of IMN, the time of treat-
ment administration and the type of immunosuppres-
sion remain unclear.
According to the KDIGO (Kidney Disease: Improving
Global Outcomes), a combination of corticosteroids and
cytotoxic drugs (chlorambucil or oral cyclophospha-
mide) can induce remission of nephrotic syndrome in
patients with IMN [3]. However, the possible side effects
of this standard therapy, including myelosuppression,
infection, and thrombosis, can lead refusal of the therapy
by the patients [4, 5]. A recent placebo-controlled study
suggested that tacrolimus (TAC) monotherapy was effect-
ive for IMN [6]. In a randomised control trial by Min
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Chen et al., the remission rate was found to be higher and
the decrease in urinary protein levels was found to be
greater in IMN patients treated with TAC plus predisone
as compared to those receiving cyclophosphamide (com-
bined with predisone) [7]. In a previous study, we also
observed that earlier initiation of therapy with TAC (com-
bined with predisone) over 24 weeks was useful for ameli-
orating the severity of proteinuria in Chinese adults with
IMN [8]. Although TAC can induce remission in most
patients with IMN, the high relapse rates after treatment
withdrawal, associated renal toxicity, and heavy cost bur-
den are major concerns [9]. Hence, there is a need to
explore alternative therapeutic strategies for IMN.
Tripterygium wilfordii Hook F (TwHF)—one of the
most widely studied Chinese medicinal plants—is a
member of the Celastraceae family of perennial vine-like
plants. Tripterygium wilfordii multiglycosides is a prep-
aration that is extracted and purified from the root
xylem of TwHF [10], and is commercially available as
tablets. Tripterygium wilfordii multiglycosides exerts
both anti-inflammatory and immunosuppressive effects
[11–13], and has been extensively used in China for the
treatment of autoimmune diseases, such as rheumatoid
arthritis [14], systemic lupus erythematosus (SLE) [15],
and nephrotic syndrome [16]. Recent clinical studies in-
dicated that TWG is a promising therapeutic option for
patients with IMN [17].
In the present study, we evaluated the efficacy and
safety of tripterygium wilfordii multiglycosides plus
prednisone compared to those of TAC (combined with
prednisone) in patients with IMN.
Methods
This prospective cohort study was performed at a single
centre, the Kidney Disease Center of the First Affiliated
Hospital, College of Medicine, Zhejiang University
(Hangzhou, P. R. China). All enrolled patients were admit-
ted from January 2013 to December 2013. Before the
treatments were initiated, we obtained written informed
consent from the patients and approval from the ethics
committee of our hospital (Medical Ethics Committee of
the First Affiliated Hospital, College of Medicine, Zhejiang
University). Patients were informed about the potential
risks associated with all the drugs that they will receive.
Study population
All the enrolled patients were older than 18 years and
diagnosed with IMN by biopsy. We included patients
who met the following criteria: (1) 24-hour urinary
protein excretion of ≥3.5 g/d after 3–6 months observa-
tion of non-immunosuppressive therapy; (2) biopsy-
proven membranous nephropathy; and (3) initial serum
creatinine level of <133 μmol/L. We excluded patients if
they met any of the following conditions: (1) previous
treatment history with steroids or immunosuppressive
medications; (2) patients who were not suitable for im-
munosuppressive treatment because of the presence of
malignant tumour, gastrointestinal bleeding, human im-
munodeficiency virus or hepatitis B virus infection; (3)
secondary membranous nephropathy, such as systemic
lupus erythematosus, diabetes mellitus, or hepatitis B
virus infection; and (4) serum creatinine (Scr) levels of
≥133 μmol/L.
Indications for therapy
In this prospective cohort study, patients in the TWG
group were treated with tripterygium wilfordii multigly-
cosides combined with oral prednisone, and patients in
the TAC group received oral TAC combined with oral
prednisone. Oral prednisone was initially prescribed at
0.5 mg/kg daily for 8 weeks, and the dose was reduced
by 5 mg every two weeks to 20 mg; thereafter, the dose
was maintained for 8 weeks and tapered over 16 weeks
until complete withdrawal. In the TWG group, TWG
was administered at 20 mg three times a day (totally
60 mg per day) during the initial 16 weeks; the dose was
then reduced to 20 mg twice a day (totally 40 mg daily)
and maintained for 8 weeks, followed by total with-
drawal at the end of 36 weeks. In the TAC group, TAC
was initially administered at 0.05 mg/kg daily, divided
into 2 doses over 12-hour intervals. The dose was ad-
justed according to the trough blood level, with a target
of 4–8 ng/ml, and was tapered at the beginning of the
12–24-week period according to the response; total
withdrawal was ensured at the end of 36 weeks. With
regard to patients with no response (NR) to the therap-
ies or relapse during the therapy, those in the TWG
group were recommended to quit the trial and undergo
treatment with TAC and predisone, whereas those in the
TAC group were recommended to quit the trial and
undergo treatment with TWG and predisone. In our study,
the multiglycosides preparation was made by Zhejiang
DND Pharmaceutical Co., Ltd (Zhejiang, China)—each tab-
let contained 10 mg of the extract from the root xylem of
Tripterygium wilfordii Hook F.
Follow-up was performed on a weekly basis for the first
4 weeks, after which follow-up was performed on a
monthly basis. After the initiation of TAC treatment, we
monitored the blood concentration of TAC in the patients
each week and adjusted the dosage until stable levels of
TAC were achieved. The serum levels of creatinine, glu-
cose, albumin, alanine aminotransferase, and lipids, as well
as complete blood counts and 24-hour urinary protein
excretion were measured at each visit during the study
period. The glomerular filtration rate (GFR) was estimated
using the 4-variable Modification of Diet in Renal Disease
(MDRD) study equation: GFR = 186 × serum creatin-
ine(−1.154) × age(−0.203) × 1.212 (if African-American) ×
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0.742 (if female). Patients were also asked to report any
adverse effects immediately or at each follow-up visit.
Outcome variables and definitions
The primary outcome was the remission rate, including
CR and PR. The secondary outcomes included the time
to remission, relapse rate, changes in serum albumin
levels, daily urinary protein levels, estimated glomerular
filtration rate (eGFR), and adverse effects. CR was
defined as a decrease in the daily urinary protein level to
≤0.3 g, whereas PR was defined as a reduction in the
urinary protein level to 0.3–3.5 g/d along with a 50 %
reduction from its peak values. Moreover, no response
(NR) was defined as the persistence of nephrotic pro-
teinuria after 12 weeks of treatment with TWG (60 mg
per day) or TAC (with through blood level of 4–8 ng/
mL). Time to remission was defined as the time from
the initiation of therapy to the first day when CR or PR
was observed. Relapses were defined as the observation
of urinary protein levels in the nephritic range after a PR
or CR, or an increase in the daily urinary protein levels
by >50 % in patients who had previously shown a >50 %
improvement in urinary protein levels without reaching
a value of ≤0.3 g/day.
Statistical analysis
Continuous variables are expressed as means ± standard
deviation and categorical variables are presented as num-
ber/percentage. We compared the differences for normally
distributed continuous variables between groups by using
independent t-tests and non-normally distributed vari-
ables by using the Mann–Whitney test. Fisher’s exact test
was used to compare the percentage of CR or PR in the 2
groups. The probability of remission or CR was analysed
using Kaplan-Meier curves, and differences were esti-
mated by using the log-rank test. All P values were 2-
sided, and significance was set at a P value of 0.05. All the
analyses were performed using SPSS version 19.0.
Results
A total of 53 patients with IMN met the inclusion cri-
teria, including 23 in the TWG group and 30 in the TAC
group. The baseline characteristics in the 2 groups were
similar (Table 1), and the patients were followed up until
April 1, 2015. All patients completed the study and were
included in subsequent analyses of efficacy and safety.
The treatment protocol was switched in 8 patients (3 in
the TWG group and 5 in the TAC group) because of
relapse or NR (4 cases of NR, 4 cases of relapse) to the
initial therapy.
Response to therapy
CR and PR in patients in both groups during the 36-week
therapy period are shown in Fig 1. During the 36-week
therapy period, the percentages of remission (either PR or
CR) in the TWG and TAC groups were 82.6 % and
83.3 % at 12 weeks (p > 0.05), 86.9 % and 86.6 % at
24 weeks (p > 0.05), and 86.9 % and 90.0 % at 36 weeks
Table 1 Baseline Characteristics of Patients Receiving Tripterygium Wilfordii Multiglycosides or Tacrolimus
TAC group (n = 30) TWG group (n = 23) p value
Sex (female) 8(26.70 %) 11(47.80 %) 0.93
Age (years) 43.40 ± 16.10 48.82 ± 6.80 0.11
BMI (kg/m2) 23.79 ± 3.01 22.75 ± 3.16 0.28
Daily urinary protein (g) 6.32 ± 3.37 6.80 ± 2.25 0.54
Serum albumin (g/l) 23.51 ± 7.39 28.04 ± 9.86 0.06
Scr (μmol/l) 80.17 ± 30.24 66.04 ± 19.71 0.06
BUN (mmol/l) 5.96 ± 3.75 5.22 ± 2.73 0.43
UA (umol/l) 344.97 ± 136.04 340.65 ± 71.92 0.88
eGFR(MDRD) (ml/min) 83.70 ± 34.29 100.92 ± 28.27 0.06
Hb (g/l) 139.69 ± 17.19 133.74 ± 15.15 0.20
TG (mmol/l) 2.36 ± 1.82 2.57 ± 1.51 0.66
Tch (mmol/l) 8.38 ± 2.44 7.34 ± 2.38 0.13
LDL (mmol/l) 4.70 ± 0.61 4.88 ± 0.69 0.33
HDL (μmmol/l) 1.57 ± 0.48 1.56 ± 0.52 0.90
Blood glucose (mg/dl) 4.70 ± 0.61 4.88 ± 0.69 0.33
ALT (u/l) 24.40 ± 10.51 17.20 ± 6.18 0.15
Note: Data are expressed as mean ± standard deviation or number and (%). p values are calculated by analysis of variance, χ2 test, or independent t-test,
as appropriate
BMI Body Mass Index; Scr serum creatinine; BUN blood urea nitrogen; UA Uric acid; eGFR estimated glomerular filtration rate; Hb haemoglobin; TG Triglyceride; Tch
Total cholesterol; LDL Low density lipoprotein; HDL High density lipoprotein
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(p > 0.05), respectively. The percentages of CR in the
TWG and TAC groups were 17.4 % and 16.7 % at 12 weeks
(p > 0.05), 39.1 % and 26.7 % at 24 weeks (p > 0.05), and
52.2 % and. 46.7 % at 36 weeks (p > 0.05), respectively. The
mean time to remission in the TWG group (11.8 ±
12.5 weeks; range, 1–36 weeks) was similar (p > 0.05) to
that in the TAC group (8.5 ± 9.1 weeks; range, 1–36
weeks). The probability of remission (either CR or
PR) and CR, estimated using the Kaplan-Meier
method, showed no significant differences between
the 2 groups (Fig 2). After 12 weeks of treatment, NR
was recorded in 4 (17.4 %) patients in the TWG
group and 4 (13.3 %) patients in the TAC group (p >
0.05). Among patients with NR, 4 (2 in TWG group
and 2 in the TAC group) switched treatment to the
corresponding protocol, but still did not achieve re-
mission. The other 4 patients (2 in the TWG group
and 2 in the TAC group) continued to receive the
original therapy, including 3 (1 in the TWG group
and 2 in the TAC group) who subsequently achieved
PR and 1 (from the TWG group) who remained re-
sistant to therapy.
Among the patients who at least experienced PR, 4 of
23 TWG patients (17.4 %) and 7 of 30 TAC patients
(23.3 %) exhibited a relapse within the TWG or TAC
treatment period (p > 0.05). The mean follow-up period
after therapy was 10.6 ± 5.8 months (TWG group: 10.2
± 6.3 months, range: 0.3–15 months; TAC group: 10.9 ±
5.5 months, range: 0.5–15 months). Moreover, relapse
occurred in 4 (17.4 %) TWG patients and 6 (20 %) TAC
patients (p > 0.05) during the follow-up period after ces-
sation of treatment.
Figure 3a and b show the daily urinary protein and serum
albumin levels of patients before treatment (week 0), during
therapy, and at the last follow-up. In the TWG group, 24-
hour urinary protein excretion improved from 6.8 ± 2.3 g/
day at baseline to 3.4 ± 3.1 g/day at week 12 (p < 0.05), 2.1
± 2.9 g/day at week 24 (p < 0.05), and 2.3 ± 3.6 g/day at
week 36 (p < 0.05), whereas serum albumin levels changed
from 28.04 ± 9.86 g/l before treatment to 27.1 ± 8.5 g/l at
week 12 (p > 0.05), 32.6 ± 6.8 g/l at week 24 (p > 0.05), and
32.9 ± 7.4 g/l at week 36 (p > 0.05). In the TAC group, the
urinary protein levels decreased from 6.3 ± 3.4 g/day at
baseline to 3.4 ± 2.8 g/day at week 12 (p < 0.05), 1.9 ± 1.6 g/
day at week 24 (p < 0.05), and 2.1 ± 1.9 g/day at week 36 (p
< 0.05), whereas serum albumin levels significantly in-
creased from 23.5 ± 7.4 g/l at baseline to 38.4 ± 7.9 g/l at
week 12, 40.7 ± 6.7 g/l at week 24, and 41.4 ± 8.1 g/l at week
36 (p < 0.05). There were no significant differences between
the 2 groups in the change of daily proteinuria (p > 0.05),
while the TAC group showed a significantly greater increase
in serum albumin levels as compared to the TWG group
(p < 0.05).
Changes in renal function during follow-up
The average baseline eGFR was similar in the TWG group
(100.92 ± 28.27 mL/min) and the TAC group (83.70 ±
34.29 mL/min) (Table 1). Figure 3c shows the eGFR of both
groups before treatment (week 0), during therapy, and at
the last follow-up (10.6 ± 5.8 months). The differences in
the eGFR between the 2 groups during therapy and the
follow-up periods were not significant (p > 0.05). At the
final follow-up, the eGFR levels remained stable in all
patients.
Fig 1 The percentage of remission (partial remission or complete remission) in patients receiving TWG or TAC during the 36 weeks of therapy,
and the percentage of remission (either PR or CR) between the 2 groups were not significantly different (p > 0.05)
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Adverse effects
Among the 53 patients, 13 adverse events were recorded
(TAC group, 7 events; TWG group, 6 events; Table 2).
These side effects included gastrointestinal symptoms (3
in the TAC group and 2 in the TWG group), menstrual
disorder (3 in the TWG group), anaemia (2 in the TAC
group and 1 in the TWG group), and new-onset glucose
intolerance (2 in the TAC group). All of the adverse
effects were mild and well controlled.
Discussion
IMN is an organ-specific autoimmune disease charac-
terised by the subepithelial formation of immune deposits
containing antigen, IgG, and complement components.
The pathogenesis of IMN involves the formation of
immune complexes and activation of the complement
system; however, the specific mechanism remains un-
known. Recently, Beck et al. reported that approximately
70 % of patients with IMN have circulating autoantibodies
(mainly IgG4) directed against phospholipase A2 receptor
1 (PLA2R1), which is located on the surface of normal
human podocytes, and induced proteinuria [18]. These
findings facilitated progress in our understanding of the
mechanism of IMN. Induction of remission in IMN pa-
tients can improve the quality of life of patients, and may
also serve as a good predictor of the long-term outcome
[19–21]. Various immunosuppressive regimens have been
used in the treatment of IMN over the past 40 years. The
decision of when to treat and with what regimen in a
patient with IMN should consider the likelihood of a
spontaneous remission as well as the potential adverse
consequences of a exposure to immunosuppressants.
TAC is a drug of choice for IMN treatment. TAC does
not only have an immunosuppressive effect on proteinuria,
but may also exert an effect directly through cytoskeletal
stabilisation in podocytes. However, the predominance ef-
fect of TAC is currently unclear. Compared with cyclospor-
ine, TAC is a more potent inhibitor of antigen-driven T cell
activation, cytokine production, and lymphocyte prolifera-
tion in vitro [22], and is associated with greater efficacy and
less adverse effects in renal transplantation [23]. Previous
studies have indicated that the TAC plus predisone regimen
can induce a high remission rate in Chinese patients with
IMN [7, 8], and is superior to the standard therapy involv-
ing alkylating agents [24]. Moreover, TAC is also effective
in several resistant patients with IMN [25]. However, the
relatively high cost of TAC and the various associated
adverse events, such as drug-associated nephrotoxicity,
have limited the use of TAC in patients with IMN. Hence,
research on both valid and cost effective medications for
the immunosuppressive treatment of IMN is ingoing, par-
ticularly in developing countries.
Tripterygium wilfordii multiglycosides is purified from
TwHF, and has been widely used in China for the treat-
ment of nephritis more than 30 years. Recently, a meta-
analysis reported that TwHF has beneficial effects on the
remission of idiopathic refractory nephrotic syndrome
[25]. A randomised control trial conducted in China
compared the effects of TWG monotherapy and com-
bination therapy with TWG and predisone in patients
with IMN. The results showed that TWG is a useful
therapy to ameliorate proteinuria severity, and the effect
of TWG combined with predisone is significantly greater
than that of TWG monotherapy [17]. However, no study
has compared the efficacy and safety of TWG (plus pre-
disone) and TAC (plus predisone) in patients with IMN
thus far. Among the 53 adults who received 36 weeks of
therapy, 86.9 % of the patients in the TWG group and
90.0 % of patients in the TAC group achieved remission
(either CR or PR); in particular, 12 of 23 patients
(52.2 %) in the TWG group and 14 of 30 patients
(46.7 %) in the TAC group experienced CR. The mean
time to remission of the TWG protocol was similar to
that of the TAC protocol. Most patients achieved remis-
sion during the first 12 weeks in both groups. We did
not observe any significant difference in the relapses
rates during or after treatment in the TWG or TAC
group.
The multiglycosides preparation contains a variety of
components, and the mechanisms by which it exerts its
Fig 2 The probability of remission (either partial remission or complete remission) (log-rank test p = 0.42) and complete remission (log-rank test
p = 0.57) in the TWG group and TAC group
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dramatic antiproteinuric effects on IMN is not fully
explained. Evidence has suggested that triptolide is
the most abundant constituent and is responsible for
the immunosuppressive and anti-inflammatory effects
[26–28]. Previous studies indicated that triptolide can
inhibit interleukin (IL)-2 expression [29]; suppress the
expressions of COX-2 and inducible nitric oxide
synthase (iNOS) [30, 31]; and induce apoptosis in
mitogen stimulated active T-cells, and arrest the
growth of these T-cells [32]. It can also significantly
inhibit the pro-inflammatory factor-induced up-
regulation of class II MHC, B7-1, and B7-2 in the
tubular epithelial cells [33], which are known to be
involved in T-cell activation [34]. In addition to its
immunosuppressive and anti-inflammatory activity,
the therapeutic effect of triptolide may also be medi-
ated through its direct activity on the restoration of
podocyte injuries. In a recent report, the use of trip-
tolide in animals with Heymann nephritis showed that
triptolide could improve podocyte lesions and help re-
store the normal structure of the slit diaphragm [35].
Another study indicated that triptolide protects podo-
cytes by inhibiting p-38 MAPK activation and fighting
against the membrane attack complex (C5b-9) [36].
The mechanism of triptolide differs from that of pred-
nisone [29], and is also distinct from that of calcineurin in-
hibitors (CNIs; cyclosporine and TAC) [37]. Triptolide was
also more effective in preventing T cell proliferation and
interferon-gamma production than FK506 [38]. Hence,
triptolide can induce remission in patients who have no
response to prednisone and CNIs.
Although the benefits of using TWG are apparent, this
therapy has some side effects. The common adverse
effects include upset stomach, liver injury, myelosup-
pression, reversible infertility in men, and amenorrhea in
women [39, 40]. In the present study, menstrual disorders
were detected only in the TWG group, but the medication
was nevertheless well tolerated. The number of patients
with new-onset glucose intolerance was greater in the
TAC group. Moreover, it was observed that the serum
albumin level in TWG group increased less than that in
TAC group, and the underlying reason is unclear. An earl-
ier report indicated that TAC can promote albumin
synthesis in the liver [41], and we also speculate that
TWG may affect the production of albumin in the liver.
Hence, we carefully considered these effects when using
TWG in patients with low serum albumin levels.
This study is limited by its nonrandomised format, and
we suggest that larger prospective, randomised, multi-
centre trials should be performed to evaluate the efficacy
and safety of TWG in patients with IMN. Another limita-
tion of this study is that it is unclear whether the findings
can be applied to patients with IMN of other ethnic back-
grounds, as the present study only included Chinese
patients.
Conclusion
Tripterygium wilfordii multiglycosides is highly effective
for patients with IMN. The emergence of TWG therapy
Fig 3 Time course of daily urinary protein levels, serum albumin
levels, and eGFR levels in patients who received either TWG or TAC
therapy. #statistically a significant difference between the start and
end of treatment in the TWG group (p < 0.05); *statistically a
significant difference between the start and end of treatment in the
TAC group (p < 0.05); $statistically a significant difference between
the 2 groups (p < 0.05). (a) Daily proteinuria of patients in the two
group. (b) Serum albumin of patients in the two group. (c) eGFR of
patients in the two group
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has actually reduced the heavy medical burden, because
this medication is cost effective than other immunosup-
pressive remedies such as TAC, cyclosporine, and leflu-
nomide, particularly for patients in developing countries.
Therefore, TWG is a promising alternative therapy for
patients with IMN.
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